An application made for this job — a tailored resume and cover letter that speak straight to the posting.
NewLimit is seeking a Principal/Senior Scientist to drive our mRNA process development and engineering efforts. As the mRNA Drug Substance Lead, you'll own process development from research-scale production through external GMP manufacturing.
This is a hands-on, lab-focused role requiring deep expertise in optimizing IVT and purification workflows. You will report to the Sr Director of Tech Ops and help build the mRNA Process Sciences team as our pipeline grows.
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
NewLimit is seeking a Principal/Senior Scientist to drive our mRNA process development and engineering efforts. As our mRNA Drug Substance Lead, you'll own mRNA process development from research-scale production through external GMP manufacturing. This is a hands-on, partially lab-based role requiring deep expertise in optimizing IVT and purification workflows. You'll be reporting directly to our Sr Director of Tech Ops and building out the mRNA Process Sciences team as our pipeline grows.
As a member of our team, you will:
NewLimit offers generous benefits to ensure our team can focus on our mission:
Salary Range: $170,000 to $200,000. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. NewLimit offers a competitive benefits package, which includes a 401k, healthcare coverage, and 20 days of PTO. Learn more at: https://www.newlimit.com/careers *This compensation and benefits information is based on Company's good faith estimate as of the date of publication and may be modified in the future.